相似文献
1
Liver fibrosis.
Turk J Gastroenterol. 2018 Jan;29(1):14-21. doi: 10.5152/tjg.2018.17330.
2
Intercellular crosstalk of hepatic stellate cells in liver fibrosis: New insights into therapy.
Pharmacol Res. 2020 May;155:104720. doi: 10.1016/j.phrs.2020.104720. Epub 2020 Feb 21.
3
Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology.
Nat Commun. 2013;4:2823. doi: 10.1038/ncomms3823.
4
Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis.
Tohoku J Exp Med. 2013 Jan;229(1):35-43. doi: 10.1620/tjem.229.35.
5
SIRT1 antagonizes liver fibrosis by blocking hepatic stellate cell activation in mice.
FASEB J. 2018 Jan;32(1):500-511. doi: 10.1096/fj.201700612R. Epub 2017 Sep 26.
6
Molecular and cellular mechanisms of liver fibrosis and its regression.
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166. doi: 10.1038/s41575-020-00372-7. Epub 2020 Oct 30.
7
Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells.
Vitam Horm. 2016;102:121-49. doi: 10.1016/bs.vh.2016.04.011. Epub 2016 May 31.
8
Wnt signaling in liver fibrosis: progress, challenges and potential directions.
Biochimie. 2013 Dec;95(12):2326-35. doi: 10.1016/j.biochi.2013.09.003. Epub 2013 Sep 13.
9
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
World J Gastroenterol. 2016 Dec 28;22(48):10512-10522. doi: 10.3748/wjg.v22.i48.10512.
10
Liver: hepatic stellate cells hold the key to liver fibrosis.
Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):74. doi: 10.1038/nrgastro.2013.244. Epub 2013 Dec 10.
引用本文的文献
1
M2 Macrophages-Based Immunotherapy: A New Therapeutic Approach in Liver Fibrosis.
Adv Pharm Bull. 2025 Jun 2;15(2):314-325. doi: 10.34172/apb.025.43855. eCollection 2025 Jul.
2
alleviates liver fibrosis via modulation of purine metabolism and NF-κB signaling pathway: insights from multi-omics analysis.
Front Pharmacol. 2025 Aug 1;16:1630927. doi: 10.3389/fphar.2025.1630927. eCollection 2025.
3
Dual Roles of SIRT7 Inhibition by Oroxylin A Reprogram HSCs Fate: PRMT5 Succinylation-Driven Senescence and Ecto-Calreticulin-Dependent NK Cell Immune Clearance in Liver Fibrosis.
Research (Wash D C). 2025 Aug 7;8:0808. doi: 10.34133/research.0808. eCollection 2025.
4
Higher plasma dicarbonyl levels are associated with liver fibrosis in obese individuals.
Diabetes Obes Metab. 2025 Jul 29. doi: 10.1111/dom.16643.
5
Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets.
World J Gastroenterol. 2025 Jul 7;31(25):107260. doi: 10.3748/wjg.v31.i25.107260.
6
When liver disease diagnosis encounters deep learning: Analysis, challenges, and prospects.
ILIVER. 2023 Mar 4;2(1):73-87. doi: 10.1016/j.iliver.2023.02.002. eCollection 2023 Mar.
7
Therapeutic Potential of Alginate-Pectin-Chitosan Encapsulated Pediococcus acidilactici Against Bile Duct Ligation-Induced Hepatic Fibrosis in Rats.
Probiotics Antimicrob Proteins. 2025 Jun 27. doi: 10.1007/s12602-025-10625-z.
8
Identification and validation of the fibrosis-related molecular subtypes of hepatocellular carcinoma by bioinformatics.
Discov Oncol. 2025 Jun 23;16(1):1180. doi: 10.1007/s12672-025-02964-8.
9
The multifaced role of the macrophage migration inhibitory factor family in organ fibrosis.
Am J Physiol Cell Physiol. 2025 Jul 1;329(1):C119-C135. doi: 10.1152/ajpcell.00198.2025. Epub 2025 May 30.
10
Engineered exosomes: a promising drug delivery platform with therapeutic potential.
Front Mol Biosci. 2025 May 9;12:1583992. doi: 10.3389/fmolb.2025.1583992. eCollection 2025.
本文引用的文献
1
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
World J Gastroenterol. 2016 Dec 28;22(48):10512-10522. doi: 10.3748/wjg.v22.i48.10512.
2
Clinical Advancements in the Targeted Therapies against Liver Fibrosis.
Mediators Inflamm. 2016;2016:7629724. doi: 10.1155/2016/7629724. Epub 2016 Nov 24.
3
Controversies over the Epithelial-to-Mesenchymal Transition in Liver Fibrosis.
J Clin Med. 2016 Jan 14;5(1):9. doi: 10.3390/jcm5010009.
4
Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.
EJNMMI Res. 2015 Dec;5(1):71. doi: 10.1186/s13550-015-0151-x. Epub 2015 Dec 9.
5
Reversibility of liver fibrosis.
Clin Res Hepatol Gastroenterol. 2015 Sep;39 Suppl 1(0 1):S60-3. doi: 10.1016/j.clinre.2015.06.015. Epub 2015 Jul 20.
6
Experimental models of liver fibrosis.
Arch Toxicol. 2016 May;90(5):1025-1048. doi: 10.1007/s00204-015-1543-4. Epub 2015 Jun 6.
7
Reversibility and heritability of liver fibrosis: Implications for research and therapy.
World J Gastroenterol. 2015 May 7;21(17):5138-48. doi: 10.3748/wjg.v21.i17.5138.
8
Recent advancement of molecular mechanisms of liver fibrosis.
J Hepatobiliary Pancreat Sci. 2015 Jul;22(7):512-8. doi: 10.1002/jhbp.245. Epub 2015 Apr 13.
9
Angiogenesis and liver fibrosis.
World J Hepatol. 2015 Mar 27;7(3):377-91. doi: 10.4254/wjh.v7.i3.377.
10
Origin of myofibroblasts in the fibrotic liver in mice.
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3297-305. doi: 10.1073/pnas.1400062111. Epub 2014 Jul 29.
Zotero 插件